Trial · NCT03085758
Outcomes39
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 39
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Mortality) | 90 days | Full Analysis Set | days | MEAN |
| PRIMARY | Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Interruption of Infusion) | 90 days | Safety Analysis Set | Interruptions | NUMBER |
| PRIMARY | Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Frequency of TEAEs) | 90 days | Safety Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Mild Severity | 90 days | Safety Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Moderate Severity | 90 days | Safety Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Severity and Frequency of TEAEs) - Severe Severity | 90 days | Safety Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Efficacy to be Determined by Sepsis Support Index (SSI) | 14 days | Full Analysis Set | score on a scale | MEAN |
| SECONDARY | Sepsis Support Index (SSI) | 28 days | Full Analysis Set | score on a scale | MEAN |
| SECONDARY | Penalized Sepsis Support Index (pSSI) at 14 Day Follow-up | day 14 | Full Analysis Set | score on a scale | MEAN |
| SECONDARY | Persistent Organ Dysfunction or Death at 14 and 28 Day Follow-up | day 14 and day 28 | Full Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Mortality Rate | day 28 | Full Analysis Set | days | MEAN |
| SECONDARY | SSI and pSSI Excluding the Renal Component | day 14 and day 28 | Full Analysis Set | score on a scale | MEAN |
| SECONDARY | SSI Weighted for Mortality | day 14 | Full Analysis Set | score on a scale | MEAN |
| SECONDARY | Individual Sepsis Support Index Components | day 14 and day 28 | Full Analysis Set | score on a scale | MEAN |
| SECONDARY | Sequential Organ Failure Assessment (SOFA) Score : Composite Measure: SOFA Score and Its Changes Over Time | 28 days | Full Analysis Set | score on a scale | MEAN |
| SECONDARY | Change in Renal Function (Creatinine) | day 1, day 3 and day 7 | Full Analysis Set | μmol/L | MEAN |
| SECONDARY | Duration of Stay at ICU/ Hospital | 90 days | Full Analysis Set | days | MEAN |
| SECONDARY | Changes of Functional Parameter Mean Arterial Pressure During Stay at ICU | 28 days | Full Analysis Set | mmHg | MEAN |
| SECONDARY | Changes of Functional Parameter Creatinine During Stay at ICU | 28 days | Full Analysis Set | μmol/L | MEAN |
| SECONDARY | Changes of Functional Parameter Partial Pressure of Oxygen in Arterial Blood(PaO2) / Fraction of Inspired Oxygen (FiO2) During Stay at ICU | 28 days | Full Analysis Set | ratio | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03085758/outcomes